EOLS earnings: real EPS beat/miss history, analyst consensus Buy, P/E -8.82. Updated 2026-07-23.
Evolus (EOLS) Research Hub
Evolus (EOLS) trades on NASDAQ, US in the Healthcare (Drug Manufacturers - Specialty & Generic) sector. As of 2026-09-11, shares last closed at 7.84 USD (-8.52%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.82, market cap 0.38B. This hub links to the full technical, earnings and options research available for EOLS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Drug Manufacturers - Specialty & Generic) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 7.84 USD (-8.52%) |
| 52-week range | 5.45 USD – 9.31 USD |
| Trend regime | Range |
| 14-day RSI | 52.4 (Neutral) |
| Trailing P/E | -8.82 |
| Market cap | 0.38B |
| Dividend yield | 0.00% |
Available research for EOLS
Covered Call on EOLS: how it works, illustrative setup around the real 7.84 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EOLS: how it works, illustrative setup around the real 7.84 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EOLS: how it works, illustrative setup around the real 7.84 USD price, max profit/loss, breakeven and when to use it. Educational.
EOLS technical analysis: range, last 7.84 USD, RSI 52.4, 52w range 5.45 USD–9.31 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is EOLS in?
Evolus (EOLS) is classified under Healthcare (Drug Manufacturers - Specialty & Generic), listed on NASDAQ, US.
Is EOLS in an uptrend or downtrend?
As of 2026-09-11, EOLS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EOLS's trailing P/E ratio?
EOLS's trailing P/E is -8.82, with a market cap of 0.38B. See the earnings research page for full valuation detail.